Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7387364 | 0.87 | HRH4 (0.57) | MEN1ALDH1A1HPGDKMT2ASLC15A1 | |
| SCHEMBL14628581 | 0.86 | REN (0.51) | MEN1ALDH1A1HPGDKMT2AMMEL1 | |
| Hydrochloric Acid SCHEMBL5492506 | 0.86 | HRH4 (0.56) | MEN1ALDH1A1HPGDKMT2ASLC15A1 | |
| Hydrochloric Acid SCHEMBL5492509 | 0.86 | HRH4 (0.56) | MEN1ALDH1A1HPGDKMT2ASLC15A1 | |
| SCHEMBL29580045 | 0.81 | KMT2A (0.55) | MEN1ALDH1A1HPGDKMT2ASLC15A1 | |
| Hydrochloric Acid SCHEMBL5494849 | 0.81 | HDAC8 (0.49) | SLC15A1 | |
| SCHEMBL12202915 | 0.80 | MEN1 (0.62) | MEN1ALDH1A1HPGDKMT2AHTT | |
| SCHEMBL14598315 | 0.79 | CTSS (0.64) | MEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL18554061 | 0.79 | REN (0.64) | — | |
| SCHEMBL20474604 | 0.79 | REN (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | SIRCAR JAGADISH C | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004644-A1 | Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | CETP, LDLR, NPC1L1 | MEN1 4300/4885ALDH1A1 4076/4885HPGD 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.